2 results
Approved WMORecruiting
Primary objective: To determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous…
Approved WMOCompleted
Primary objectives are:1.1) to study the effect of oral administration of morphine SR on health-related quality of life; 1.2) to explore whether morphine SR leads to respiratory adverse effects in patients with advanced COPD. Secondary objectives…